HCV Infection: Clinical Trials

12 trials for HCV Infection, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

12 completed. 12 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	12	Completed 12

Follow HCV Infection: new trials by email Literature Review of HCV Infection trials Research Report on HCV Infection

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic	Phase 2	Completed	Atea Pharmaceuticals, Inc.	10	2019-06-20	2020-05-04
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules - HCV Infection	Phase 2	Completed	Merck Sharp & Dohme LLC	57	2018-01-25	2023-05-31
Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study LDV/SOF, RBV - HCV Infection	Phase 2	Completed	Gilead Sciences	100	2014-07-01	2018-11-19
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency SOF, RBV, LDV/SOF - HCV Infection	Phase 2	Completed	Gilead Sciences	38	2013-10-07	2018-08-08
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection LDV/SOF, RBV, Placebo to match LDV/SOF - HCV Infection	Phase 2	Completed	Gilead Sciences	155	2013-10-01	2018-11-16
Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation Boceprevir, Peg-Interferon α-2b or Peg-Interferon α-2a, Ribavirin - HCV Infection, Liver Cirrhosis, Experimental	Phase 2	Completed	French National Agency for Research on AIDS and Viral Hepatitis	58	2012-01-06	2026-04-07
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection GS-9256, GS-9190, Ribavirin - HCV Infection	Phase 2	Completed	Gilead Sciences	46	2010-02-01	2012-05-31
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) PegIFN-2b, RBV, Placebo to Boceprevir - HIV Infections, Hepatitis C	Phase 2	Completed	Merck Sharp & Dohme LLC	99	2009-11-01	2017-04-07
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection placebo, ANA598, Peginterferon - HCV Infection	Phase 2	Completed	Hoffmann-La Roche	97	2009-09-01	2017-03-31
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection placebo, GS-9190, Peginterferon Alfa 2a - HCV Infection	Phase 2	Completed	Gilead Sciences	252	2008-10-01	2013-11-05
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies Blood sample collection only, ABT-333 - HCV Infection	Phase 2	Completed	AbbVie (prior sponsor, Abbott)	35	2008-08-01	2015-01-08
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV GS-9450, GS-9450 Placebo - HCV Infection	Phase 2	Completed	Gilead Sciences	33	2008-04-01	2014-06-19

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding